10X Genomics Inc

Análisis de la acción 10X Genomics Inc (TXG)

$61.540

-3.139 (-5.10%)Al cierre

Loading chart…
High
65.000
Open
63.880
VWAP
62.45
Vol
2.36M
Mkt Cap
2.38B
Low
60.820
Amount
147.47M
EV/EBITDA, TTM
-8.95

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

Métricas de valoración

The current forward P/E ratio for 10X Genomics Inc (TXG) is -9.54, compared to its 5-year average forward P/E of -60.45.

Forward P/E

Fair
5Y Average P/E
-60.45
Current P/E
-9.54
Sobrevalorada
48.65
Infravalorada
-169.56

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-576.19
Current EV/EBITDA
-8.95
Sobrevalorada
1418.56
Infravalorada
-2570.94

Forward P/S

Fair
5Y Average P/S
9.29
Current P/S
2.27
Sobrevalorada
16.71
Infravalorada
1.87

Alphio AI Price Scenarios for TXG

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TXG

$7.67

Precio del escenario

B

Base

Base · 50%TXG

$7.57

Precio del escenario

B

Bear

Bear · 25%TXG

$6.64

Precio del escenario

Whales holding TXG

H

Hillsdale Investment Management Inc.

+ HoldingTXG

+8.85%

3M Return

S

Sprott Inc.

+ HoldingTXG

+8.33%

3M Return

B

Baker Steel Capital Managers LLP

+ HoldingTXG

+7.33%

3M Return

A

ARK Investment Management LLC

+ HoldingTXG

+4.40%

3M Return

D

Davy Global Fund Management Limited

+ HoldingTXG

+2.50%

3M Return

H

Harvard Management Company, Inc.

+ HoldingTXG

+2.22%

3M Return

Cronología de eventos

2026-08-28 (ET)

15:00:00

10x Genomics Awarded $4.8M for Parse Biosciences Infringement

2026-08-06 (ET)

19:00:00

Stock Futures Mixed as Doximity Soars 83.93%

2026-07-29 (ET)

09:30:00

10x Genomics Partners with Lausanne University Hospital to Advance Cancer Diagnostics Research

2026-06-17 (ET)

09:30:00

10x Genomics Collaborates with Cleveland Clinic on Bladder Cancer Diagnostics Research

2026-06-09 (ET)

09:20:00

10x Genomics Acquires New Company

Noticias

TXG FAQ — answered by Alphio AI

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis